We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Ardelyx Inc
39 own
41 watching
Current Price
$0
$0.04
(1.03%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
842.84M
52-Week High
5.125
52-Week Low
0.4902
Average Volume
0.36M
Dividend Yield
--
P/E Ratio
--
Market Capitalization842.84M52-Week High5.12552-Week Low0.4902Average Volume0.36MDividend Yield--P/E Ratio--What does the Ardelyx Inc do?
Ardelyx, Inc. develops and sells therapeutics for the treatment of cardio renal and gastrointestinal diseases in the United States. Its lead product candidate is tenapanor, which is in Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. The company is also developing RDX7675, which is in Phase III clinical trial for the treatment of people with hyperkalemia; and RDX8940 in Phase I clinical trial for the treatment of patients with NASH and other gastrointestinal indications. Its drug candidates in the stages of research and development include RDX013 for the treatment of patients with hyperkalemia; RDX011 for the discovery and development of second-generation NHE3 inhibitors; and RDX023 for the discovery and development of gut-biased FXR agonists for the treatment of GI and inflammatory diseases. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was founded in 2007 and is headquartered in Fremont, California.
Read More
How much money does Ardelyx Inc make?
News & Events about Ardelyx Inc.
Zolmax
1month ago
StockNews.com upgraded shares of Ardelyx (NASDAQ:ARDX Get Rating) from a hold rating to a buy rating in a research note published on Wednesday. Separately, Wedbush increased their target price on Ardelyx from $6.00 to $7.00 and gave the stock an outperform rating in a research note on Monday, April ...
Globe Newswire
1month ago
WALTHAM, Mass., May 01, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that additional data supporting the...
Zolmax
1month ago
Ardelyx, Inc. (NASDAQ:ARDX Get Rating)s share price reached a new 52-week high during mid-day trading on Monday after Wedbush raised their price target on the stock from $6.00 to $7.00. Wedbush currently has an outperform rating on the stock. Ardelyx traded as high as $5.13 and last traded at $4.98...
Ticker Report
2 months ago
StockNews.com lowered shares of Ardelyx (NASDAQ:ARDX Get Rating) from a buy rating to a hold rating in a report published on Wednesday. Several other equities analysts have also recently issued reports on the company. Citigroup boosted their price target on Ardelyx from $6.00 to $7.00 and ...
Zolmax
2 months ago
StockNews.com cut shares of Ardelyx (NASDAQ:ARDX Get Rating) from a buy rating to a hold rating in a research report sent to investors on Wednesday. Other equities research analysts also recently issued research reports about the company. Citigroup lifted their target price on Ardelyx from $6.00 to...
Frequently Asked Questions
Frequently Asked Questions
What is Ardelyx Inc share price today?
Can Indians buy Ardelyx Inc shares?
How can I buy Ardelyx Inc shares from India?
Can Fractional shares of Ardelyx Inc be purchased?
What are the documents required to start investing in Ardelyx Inc stocks?
What is today’s traded volume of Ardelyx Inc?
What is today’s market capitalisation of Ardelyx Inc?
What is the 52-Week High and Low Range of Ardelyx Inc?
What percentage is Ardelyx Inc down from its 52-Week High?
What percentage is Ardelyx Inc up from its 52-Week Low?
Current Price
$0
$0.04
(1.03%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.